Literature DB >> 9885944

Outcome after radiotherapy of primary spinal cord glial tumors.

M P McLaughlin1, J M Buatti, R B Marcus, B L Maria, P J Mickle, A Kedar.   

Abstract

Primary spinal cord tumors are rare, and treatment recommendations are therefore difficult. We reviewed a 22-year experience of postoperative radiotherapy for spinal cord tumors to elucidate prognostic factors and recommendations. Twenty-two patients with spinal cord tumors were treated from 1969-1991. Ten patients had ependymomas, of which two were high grade. Twelve had astrocytomas, of which 4 were high grade. Karnofsky status, age, extent of resection, tumor histology, grade, and radiation dose were evaluated, as well as degree of clinical improvement after treatment based on change in Karnofsky status. Ependymomas achieved 100% local control with postoperative radiotherapy. Grade and dose were of indeterminate significance because of these excellent results. High-grade astrocytomas all recurred and caused death. Disease recurred in 1 of 8 patients with low-grade astrocytic or mixed astrocytic tumors. The only prognostic variables of significance were histology, grade, and change in Karnofsky status after treatment. Radiation of primary spinal cord tumors is rare. In nearly all cases, local fields may be used. Improvement in Karnofsky status after radiotherapy may predict better survival. Treatment recommendations for these rare tumors are discussed.

Entities:  

Mesh:

Year:  1998        PMID: 9885944     DOI: 10.1002/(SICI)1520-6823(1998)6:6<276::AID-ROI5>3.0.CO;2-6

Source DB:  PubMed          Journal:  Radiat Oncol Investig        ISSN: 1065-7541


  10 in total

Review 1.  Radiation therapy and the management of intramedullary spinal cord tumors.

Authors:  S R Isaacson
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Prognostic factors in intramedullary astrocytomas: a literature review.

Authors:  Vladimír Benes; Pavel Barsa; Vladimír Benes; Petr Suchomel
Journal:  Eur Spine J       Date:  2009-06-28       Impact factor: 3.134

3.  Intramedullary low-grade astrocytomas: long-term outcome following radical surgery.

Authors:  G I Jallo; S Danish; L Velasquez; F Epstein
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 4.  Intramedullary ependymomas: clinical presentation, surgical treatment strategies and prognosis.

Authors:  T H Schwartz; P C McCormick
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

5.  Hypofractionated radiotherapy boost for dose escalation as a treatment option for high-grade spinal cord astrocytic tumor.

Authors:  Norio Katoh; Hiroki Shirato; Hidefumi Aoyama; Rikiya Onimaru; Keishiro Suzuki; Kazutoshi Hida; Kazuo Miyasaka; Yoshinobu Iwasaki
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

6.  A color-coded orthotopic nude-mouse treatment model of brain-metastatic paralyzing spinal cord cancer that induces angiogenesis and neurogenesis.

Authors:  K Hayashi; K Yamauchi; N Yamamoto; H Tsuchiya; K Tomita; M Bouvet; J Wessels; R M Hoffman
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

7.  Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium.

Authors:  H Kimura; L Zhang; M Zhao; K Hayashi; H Tsuchiya; K Tomita; M Bouvet; J Wessels; R M Hoffman
Journal:  Cell Prolif       Date:  2009-11-18       Impact factor: 6.831

8.  The history of ependymoma management.

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2009-05-21       Impact factor: 1.475

Review 9.  Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.

Authors:  Wook Ha Kim; Wook-Ha Kim; Sang Hoon Yoon; Chae-Yong Kim; Ki-jeong Kim; Min Mi Lee; Gheeyoung Choe; In-Ah Kim; Jee Hyun Kim; Yu Jung Kim; Hyun-Jib Kim
Journal:  J Neurooncol       Date:  2010-06-05       Impact factor: 4.506

10.  A reproducible model of intramedullary spinal cord tumor in rats bearing RG2 cells.

Authors:  Yuandong Zhuang; Wei Zhao; Weiqiang Zhang; Hao Wei; Xinming Huang; Gangfeng Cai; Chaofeng Fu; Chunhua Wang; Rui Wang; Songsheng Shi; Weizhong Yang; Chunmei Chen
Journal:  Oncotarget       Date:  2017-05-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.